

The role of AI-2-mediated quorum sensing in gut microbiome-immune dysbiosis

Anna Hawkins
University of Calgary

anna.hawkins@ucalgary.ca

Microbes colonize the gastrointestinal tract, forming microbiomes essential for gut function, immune responses, and other host systems¹. Patients requiring life-support treatment develop profound gut microbiome ecology alterations, characterized by a loss of beneficial commensals and overgrowth of potential pathogens (pathobionts), including *Enterobacteriaceae* and *Enterococcaceae* families^{2,3}. This increases patients' risk of adverse outcomes, including nosocomial infections, by driving systemic immune dysregulation^{4,5}. Prior research suggests that inter-microbe molecular communication (quorum sensing) contributes to pathobiont overgrowth in ICU patients' guts^{6,7}. The quorum-sensing molecule AI-2 contributes to gut microbiome dysbiosis, yet its role in critical illness is poorly understood^{8,9}. This project aims to understand the contribution of altered *Enterobacteriaceae* AI-2 signalling towards gut microbiome dysbiosis and host immune dysfunction in critical illness. We will screen a library of ICU-patient-derived *Enterobacteriaceae* isolates and bioreactor-cultured fecal microbiomes against healthy human-derived samples to assess AI-2 concentration and activity. Next, we will utilize AI-2-deficient mutant bacteria and over-expressing controls to test whether AI-2 enables pathobiont overgrowth in germ-free and gnotobiotic mice. Lastly, we will use patient isolates and mutants to determine the impact of AI-2 on the host immune response to ICU gut microbiome dysbiosis in gnotobiotic mice. Through this, the effects of AI-2 signalling on pathogenic gut bacteria colonization resistance, inflammation, and patient outcomes will be defined. Our results will provide a mechanistic understanding of the role of gut dysbiosis in adverse outcomes in ICU patients and inform the development of targeted treatments or biomarkers for this patient population.

References

1. Jandhyala, S. M. *et al.* Role of the normal gut microbiota. *World J Gastroenterol* **21**, 8787–8803 (2015).
2. Dickson, R. P. The microbiome and critical illness. *Lancet Respir Med* **4**, 59–72 (2016).
3. Piccioni, A. *et al.* The Gut Microbiome in Sepsis: From Dysbiosis to Personalized Therapy. *J Clin Med* **13**, 6082 (2024).
4. Schlechte, J. *et al.* Dysbiosis of a microbiota–immune metasytem in critical illness is associated with nosocomial infections. *Nat Med* **29**, 1017–1027 (2023).
5. Cho, N. A., Strayer, K., Dobson, B. & McDonald, B. Pathogenesis and therapeutic opportunities of gut microbiome dysbiosis in critical illness. *Gut Microbes* **16**, 2351478 (2024).
6. Cheung, G. Y. C. *et al.* Quorum-sensing control of sepsis in the coagulase-negative staphylococcal species *Staphylococcus haemolyticus*. *Cell Rep* **44**, 116349 (2025).
7. Pappenfort, K. & Bassler, B. L. Quorum sensing signal–response systems in Gram-negative bacteria. *Nat Rev Microbiol* **14**, 576–588 (2016).
8. Li, H. *et al.* Autoinducer-2 Facilitates *Pseudomonas aeruginosa* PAO1 Pathogenicity in Vitro and in Vivo. *Front Microbiol* **8**, 1944 (2017).
9. Laganenka, L. *et al.* Interplay between chemotaxis, quorum sensing, and metabolism regulates *Escherichia coli*-*Salmonella Typhimurium* interactions in vivo. *PLOS Pathogens* **21**, e1013156 (2025).

